Evolución del protocolo de trombolisis endovenosa en ataque cerebrovascular isquémico agudo: 4 años de experiencia en el Hospital Doctor Hernán Henríquez Aravena de Temuco-Chile.

Álvaro Soto V, Gladys Morales I, Marcela Grandjean B, Debora Pollak W, Carolina Del Castillo C, Pia García F, Alexis Von Johnn A, Alfonso Riquelme G

Resumen


Background: Intravenous thrombolysis (IVT) with alteplase (tissue plasminogen activator) is the standard pharmacological treatment in acute ischemic stroke (AIS), reducing disability in patients. Aim: To report the results a thrombolysis protocol during four years in a regional public hospital. Material and methods: Data from 106 consecutive patients aged 68 ± 13 years (57% men) who were treated with IVT, from May 2012 until April 2016, was analyzed. Results: The median door-to-needle time was 80 minutes (interquartile range = 57-113). The median National institute of Health Stroke Scale (NIHSS) scores on admission and at discharge were was 11.5 and 5 points respectively. At discharge, 27% of hospitalized patients had a favorable outcome (n = 99), defined as having 0 to 1 points in the modified Rankin scale. Symptomatic intracerebral hemorrhage and mortality rates were 5.7 and 14.8%, respectively. The thrombolysis rate rose from 0.7% in 2012 to 6% in 2016. Conclusions: The implementation of 24/7 neurology shifts in the Emergency Department allowed us to increase the amount and quality of IVT in our hospital, as measured by the rate of thrombolysis and by process indicators such as door-to-needle time.

Palabras clave


Fibrinolytic Therapy; Stroke; Time-to-Treatment; Thrombolytic Therapy; Tissue Plasminogen Activator

Texto completo:

PDF